MitoSense – a research and development company focused on neurodegenerative disease treatments – recently announced the successful closure of its Series Seed Funding Round led by Caydan Capital Partners, raising close to $3.5 million. The funding round will enable MitoSense to advance its innovative work in Mitochondria Organelle Transplantation (MOT).
MitoSense plans to replenish damaged mitochondria in humans afflicted with degenerative conditions, initially concentrating on Amyotrophic Lateral Sclerosis (ALS) treatment. And this technology has broad potential applications in treating Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis, and other neurodegenerative diseases.
Along with its Series Seed funding round, MitoSense is also supported by the following organizations, whose collaborations are pivotal to its success:
– Elliott Mitochondrial Research Center: Enhancing mitochondrial research capabilities.
– James A. Haley Veterans’ Hospital: Developing therapies for neurodegenerative dysfunctions in veterans.
– Walter Reed Army Institute of Research: Focusing on mitochondrial health in military personnel.
– Greenwood Genetic Center: Researching Alzheimer’s Diseases and genetic aspects of mitochondrial diseases.
– Uppsala University, Sweden, Center for Advanced Medicinal Products: Evolving patient accessible advanced medicinal products from cellular starting materials.
This funding round underscores MitoSense’s commitment to pioneering research in mitochondrial health, aligning with the broader goal of advancing human health and wellbeing.
KEY QUOTES:
“This funding, complemented by our collaborations, propels us toward improving conditions for patients with ALS and other neurodegenerative diseases. We are dedicated to continuing the legacy of Dr. Robert Elliott, MD, PhD, in this endeavor.”
– Van Hipp, Chairman of MitoSense
“MitoSense’s groundbreaking approach in mitochondrial health is pivotal. We’re proud to support their mission to transform the landscape of neurodegenerative disease treatment.”
– Rick Waldo, Managing Partner at Caydan Capital
